Exelixis stock has already delivered a very strong 243.8% return over the past 5 years, yet valuation checks still flag it as looking cheap on several measures, so investors are weighing whether the market is still underpricing the business or already baking in much of the oncology opportunity.

• A 243.8% 5 year return puts Exelixis firmly in the group of biotech stocks that have already rewarded patient holders, which naturally raises the bar for any new entry point.
• Upcoming regulatory decisions and commercialization prospects for cancer drug candidate zanzalintinib can support the current valuation, while the FDA review outcome and uncertainty around future earnings remain a key risk if expectations prove too optimistic.
• Exelixis screens as undervalued on 5 of 6 checks, which means the broader valuation work leans cheap despite the strong share price performance, according to its 5 out of 6 value score.

The issue now is whether Exelixis shares still offer a margin of safety after such strong long term returns, or whether the valuation is already reflecting most of the good news investors are hoping for around zanzalintinib and the broader oncology portfolio.

Is Exelixis a Bargain on Earnings?

The P/E ratio is a useful way to look at Exelixis because it links the current share price directly to the earnings investors are paying for today.

Exelixis trades on a P/E of about 16.9x, which sits slightly below the broader Biotechs industry average of roughly 17.2x and well below the peer group average of around 25.6x. Based on a tailored fair P/E of about 20.8x, which reflects factors such as the company’s margins, risk profile and market positioning, the current multiple implies the shares are priced at a discount to what that framework suggests.

Despite the recent regulatory focus on zanzalintinib and a cautious tone from some analysts, Exelixis still trades below this fair P/E benchmark. This indicates that the current price does not fully reflect what investors are paying for each dollar of earnings compared with similar biotech stocks.

On the P/E multiple, Exelixis stock appears inexpensive relative to both its tailored fair ratio and many peers.

The Exelixis Narrative: What Would Justify Today's Price?

To make sense of why Exelixis' P/E looks low and what that might imply, Simply Wall St Narratives spell out exactly which paths for revenue, margins and earnings would need to unfold for the stock to be worth materially more or less than its current price. Each one ties a fair value to a clear storyline about Exelixis' potential catalysts and risks on the Community page, so you can later compare which version of events aligns with how the business actually develops.

Community narratives around Exelixis sit far apart, with one side focused on oncology upside and the other on margin and pipeline risk.

Bull case: 10% undervalued

"The company's robust cash flow, substantial balance sheet, and active share repurchase program provide significant financial flexibility for opportunistic business development and licensing deals..."

Bear case: 40% overvalued

"The company's continued heavy reliance on the cabozantinib franchise, even after recent indication expansions, leaves it acutely vulnerable to patent expiration and the inevitable emergence of generic competition..."

Do you think there's more to the story for Exelixis? Head over to our Community to see what others are saying!

The Bottom Line

Exelixis still screens as undervalued on market multiples, even after a strong 5 year run, which suggests the current price leaves some room for differing views on how its earnings profile will evolve. The key question is whether that discount reflects overly cautious sentiment on oncology concentration and patent risk, or a reasonable buffer for genuine uncertainty around future earnings and the zanzalintinib opportunity. For now, the crux of the bull versus bear debate is whether Exelixis can turn its pipeline and existing franchise into durable, diversified earnings that eventually justify a higher multiple, rather than the market being right to keep pricing in a risk premium.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.